New drug shows promise in Early-Stage High-Risk leukemia trial
NCT ID NCT03766763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests the drug venetoclax as an early treatment for people with high-risk chronic lymphocytic leukemia (CLL) that hasn't caused symptoms yet. About 82 participants will take venetoclax daily for up to 18 months. The goal is to see if the drug can wipe out nearly all cancer cells in the bone marrow after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax (a targeted drug that blocks a protein helping cancer cells survive)
- What this could lead to
- If successful, this could offer a way to treat high-risk CLL early, potentially delaying disease progression and reducing the need for stronger therapies.
- What could go wrong
- This is a small, early-phase trial (82 people) with no control group, so results may not apply broadly. Venetoclax can cause side effects like tumor lysis syndrome and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bordeaux Pessac
Pessac, 33604, France
-
CH BLOIS
Blois, 41000, France
-
CHU CAEN
Caen, 14033, France
-
Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Regional Metz Thionville
Metz, 57085, France
-
Centre leon berard
Lyon, 69008, France
-
Ch Annecy
Annecy, 74374, France
-
Ch Beziers
Béziers, 34500, France
-
Ch Cote Basque
Bayonne, 64109, France
-
Chd Le Mans
Le Mans, 72000, France
-
Chd Vendee
La Roche-sur-Yon, 85925, France
-
Chu Amiens
Amiens, 80054, France
-
Chu Angers
Angers, 49933, France
-
Chu Creteil
Créteil, 94000, France
-
Chu Estaing
Clermont-Ferrand, 63000, France
-
Chu Grenoble
Grenoble, 38043, France
-
Hopital Huriez
Lille, 59037, France
-
Hopitaljean Minjoz
Besançon, 25000, France
-
Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
Tours, 37044, France
-
Hôpital Privé Sévigné
Cesson-Sévigné, 35510, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Paoli Calmette
Marseille, 130009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.